Nasdaq ticker expected to change to POAI Effective Thursday, June 13, 2019 MINNEAPOLIS , June 11, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (Nasdaq: AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery,
MINNEAPOLIS , May 21, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. , (Nasdaq: AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, announced today that its Helomics division has been selected as the
MINNEAPOLIS , May 17, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (Nasdaq: AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, announced today that Nasdaq has determined that the Company is eligible for a
Management to Host Conference Call to Review Financial Results and Provide Corporate Update at 4:30PM Today MINNEAPOLIS , May 15, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (Nasdaq: AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized
Conference Call to be held May 15, 2019 , at 4:30pm Eastern Time MINNEAPOLIS , May 13, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”) today announces that it will report First Quarter 2019 financial results for the period ended March 31, 2019 ,
MINNEAPOLIS and SAN RAFAEL, Calif. , April 18, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”) today announced a services agreement between its wholly owned subsidiary, Helomics and the National Alopecia Areata Foundation (NAAF), which serves the
Collaboration Receives $300,000 CAD Grant to Further Develop and Commercialize TumorGenesis Oncology Discovery Technologies MINNEAPOLIS , April 16, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”) today announced that its wholly owned subsidiary,
Helomics to provide CRO services and its D-CHIP artificial intelligence (AI) platform to SpeciCare for their PIONEER Initiative functional precision medicine trial PITTSBURGH , April 11, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”) today
MINNEAPOLIS , April 09, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”) today announced a collaboration between its wholly owned subsidiary, Helomics, and Viome, a new kind of healthcare company transforming health at the molecular level, to study
MINNEAPOLIS , April 05, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision Therapeutics” or “the Company”), today announced the completion of its merger with Helomics Holding Corporation (“Helomics”), which has become the Company’s wholly owned subsidiary, providing